Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gallbladder Neoplasms | 8 | 2016 | 14 | 3.300 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2016 | 656 | 2.470 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 377 | 1.440 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2016 | 537 | 1.050 |
Why?
|
| Neoplasms | 3 | 2021 | 768 | 0.980 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2024 | 43 | 0.970 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 110 | 0.940 |
Why?
|
| Receptors, Cholecystokinin | 2 | 2016 | 5 | 0.920 |
Why?
|
| Receptor, Cholecystokinin B | 2 | 2016 | 8 | 0.920 |
Why?
|
| Haplotypes | 6 | 2014 | 279 | 0.860 |
Why?
|
| Niclosamide | 1 | 2023 | 3 | 0.840 |
Why?
|
| Carcinoma | 2 | 2014 | 71 | 0.840 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 127 | 0.810 |
Why?
|
| Gallstones | 4 | 2014 | 9 | 0.770 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2021 | 7 | 0.770 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 187 | 0.730 |
Why?
|
| Genetic Variation | 3 | 2016 | 229 | 0.680 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 660 | 0.600 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 163 | 0.540 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 30 | 0.540 |
Why?
|
| Risk Factors | 7 | 2016 | 2038 | 0.520 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 123 | 0.520 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2015 | 4 | 0.510 |
Why?
|
| Endometrial Hyperplasia | 1 | 2015 | 6 | 0.510 |
Why?
|
| Cellular Reprogramming | 1 | 2015 | 8 | 0.510 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 24 | 0.510 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 19 | 0.510 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 7 | 0.500 |
Why?
|
| Adult Stem Cells | 1 | 2015 | 10 | 0.500 |
Why?
|
| Humans | 20 | 2024 | 27165 | 0.490 |
Why?
|
| Hyaluronic Acid | 1 | 2015 | 95 | 0.460 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2014 | 7 | 0.460 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 151 | 0.450 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 5 | 0.450 |
Why?
|
| Receptors, Adrenergic | 1 | 2014 | 10 | 0.450 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 146 | 0.450 |
Why?
|
| Female | 14 | 2024 | 14661 | 0.430 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 54 | 0.420 |
Why?
|
| Cell Differentiation | 1 | 2015 | 398 | 0.410 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 49 | 0.410 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 111 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2016 | 281 | 0.390 |
Why?
|
| Middle Aged | 9 | 2016 | 6912 | 0.390 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 34 | 0.390 |
Why?
|
| Adult | 8 | 2016 | 7506 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 285 | 0.360 |
Why?
|
| India | 4 | 2014 | 139 | 0.350 |
Why?
|
| Smoking | 1 | 2014 | 466 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 516 | 0.330 |
Why?
|
| Genotype | 4 | 2014 | 443 | 0.330 |
Why?
|
| Case-Control Studies | 4 | 2015 | 707 | 0.320 |
Why?
|
| Gene Frequency | 3 | 2014 | 182 | 0.310 |
Why?
|
| Alleles | 3 | 2014 | 345 | 0.310 |
Why?
|
| Animals | 6 | 2024 | 10093 | 0.290 |
Why?
|
| Male | 8 | 2016 | 13041 | 0.250 |
Why?
|
| Apoptosis | 2 | 2023 | 740 | 0.250 |
Why?
|
| Linkage Disequilibrium | 3 | 2013 | 108 | 0.240 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 7 | 0.240 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2024 | 16 | 0.240 |
Why?
|
| Cholecystokinin | 2 | 2016 | 6 | 0.230 |
Why?
|
| Gastrins | 2 | 2016 | 28 | 0.230 |
Why?
|
| Cyclin D1 | 1 | 2023 | 38 | 0.220 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 440 | 0.220 |
Why?
|
| Cathepsin B | 1 | 2023 | 4 | 0.210 |
Why?
|
| Risk | 2 | 2014 | 133 | 0.210 |
Why?
|
| Computational Biology | 2 | 2015 | 150 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 446 | 0.210 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.200 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 1271 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 153 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 32 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 312 | 0.170 |
Why?
|
| Cell Proliferation | 1 | 2023 | 775 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 567 | 0.140 |
Why?
|
| Progesterone Congeners | 1 | 2015 | 4 | 0.130 |
Why?
|
| Multifactor Dimensionality Reduction | 1 | 2015 | 1 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 37 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2015 | 32 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 27 | 0.130 |
Why?
|
| Stomach | 1 | 2016 | 42 | 0.130 |
Why?
|
| Hemangioblasts | 1 | 2015 | 2 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2015 | 75 | 0.120 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 17 | 0.120 |
Why?
|
| Pancreas | 1 | 2016 | 59 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 209 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2015 | 85 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 86 | 0.120 |
Why?
|
| Aged | 2 | 2016 | 5229 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2015 | 75 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2015 | 122 | 0.120 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 163 | 0.120 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2014 | 5 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 472 | 0.120 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 13 | 0.120 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 7 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 462 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2014 | 31 | 0.110 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 7 | 0.110 |
Why?
|
| fas Receptor | 1 | 2014 | 19 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2014 | 32 | 0.110 |
Why?
|
| Disease Progression | 1 | 2015 | 458 | 0.110 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 13 | 0.110 |
Why?
|
| Gallbladder | 1 | 2013 | 8 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 668 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 763 | 0.110 |
Why?
|
| Neurons | 1 | 2015 | 276 | 0.110 |
Why?
|
| DCC Receptor | 1 | 2013 | 1 | 0.110 |
Why?
|
| Models, Biological | 1 | 2015 | 448 | 0.110 |
Why?
|
| Hormones | 1 | 2013 | 41 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 66 | 0.100 |
Why?
|
| Sex Factors | 1 | 2013 | 452 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 227 | 0.100 |
Why?
|
| Mice | 2 | 2024 | 4478 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2024 | 155 | 0.060 |
Why?
|
| Heterografts | 1 | 2023 | 62 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2024 | 114 | 0.050 |
Why?
|
| Chromans | 1 | 2023 | 59 | 0.050 |
Why?
|
| Pelvis | 1 | 2023 | 37 | 0.050 |
Why?
|
| Protein Binding | 1 | 2024 | 637 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 96 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2023 | 98 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 26 | 0.030 |
Why?
|
| Liver X Receptors | 1 | 2014 | 21 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2014 | 123 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 76 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 262 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 300 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 7 | 0.030 |
Why?
|
| Adipogenesis | 1 | 2013 | 18 | 0.030 |
Why?
|